Validation of the 2015 Prostate Cancer Grade Groups for Predicting Long-Term Oncologic Outcomes in a Shared Equal-Access Health System
|
|
- May Lyons
- 5 years ago
- Views:
Transcription
1 Original Article Validation of the 2015 Prostate Cancer Grade Groups for Predicting Long-Term Oncologic Outcomes in a Shared Equal-Access Health System Ariel A. Schulman, MD 1 ; Lauren E. Howard, MS 2 ; Kae Jack Tay, MD 1 ; Efrat Tsivian, MD 1 ; Christina Sze, BS 1 ; Christopher L. Amling, MD 3 ; William J. Aronson, MD 4 ; Matthew R. Cooperberg, MD, MPH 5 ; Christopher J. Kane, MD 6 ; Martha K. Terris, MD 7 ; Stephen J. Freedland, MD 2,8 ; and Thomas J. Polascik, MD 1,2 BACKGROUND: A 5-tier prognostic grade group (GG) system was enacted to simplify the risk stratification of patients with prostate cancer in which Gleason scores of 6, 3 1 4, 4 1 3, 8, and 9 or 10 are considered GG 1 through 5, respectively. The authors investigated the utility of biopsy GG for predicting long-term oncologic outcomes after radical prostatectomy in an equal-access health system. METHODS: Men who underwent prostatectomy at 1 of 6 Veterans Affairs hospitals in the Shared Equal Access Regional Cancer Hospital database between 2005 and 2015 were reviewed. The prognostic ability of biopsy GG was examined using Cox models. Interactions between GG and race also were tested. RESULTS: In total, 2509 men were identified who had data available on biopsy Gleason scores, covariates, and follow-up. The cohort included men with GG 1 (909 patients; 36.2%), GG 2 (813 patients; 32.4%), GG 3 (398 patients; 15.9%), GG 4 (279 patients; 11.1%), and GG 5 (110 patients; 4.4%) prostate cancer. The cohort included 1002 African American men (41%). The median follow-up was 60 months (interquartile range, months). Higher GG was associated with higher clinical stage, older age, more recent surgery, and surgical center (P <.001) as well as increased biochemical recurrence, secondary therapy, castration-resistant prostate cancer, metastases, and prostate cancer-specific mortality (all P <.001). There were no significant interactions with race in predicting measured outcomes. CONCLUSIONS: The 5-tier GG system predicted multiple long-term endpoints after radical prostatectomy in an equal-access health system. The predictive value was consistent across races. Cancer 2017;123: VC 2017 American Cancer Society. KEYWORDS: Gleason grade, prostate cancer, race, radical prostatectomy, Shared Equal Access Research (SEARCH), survival. INTRODUCTION In the 1970s, anatomic pathologists Donald Gleason and George Mellinger published a standardized 5-tier grading system of the histologic architecture of prostate specimens for risk stratification of prostate cancer. 1 Although major pathologic revisions were incorporated in 2005 and 2014, Gleason grading remains central to contemporary clinical staging. 2,3 However, several aspects of the system present clinical challenges. Gleason sum scores range from 2 to 10, but only summed scores of 6 or greater are reported. 2 This creates potential confusion, whereby a diagnosis of Gleason sum 6 may be incorrectly considered intermediate-risk disease. 4 In addition, Gleason scores are typically incorporated into broader 3- tiered risk groups, which can obscure important prognostic differences. 5 For example, Gleason sum 7 (Gleason and 4 1 3) is considered intermediate-risk disease, with similar management recommendations, despite evidence suggesting divergent biologic behavior. 6 Similarly, Gleason sum 8 cancers seem to have a better clinical course than Gleason 9 and 10 although all 3 are considered high-risk disease. 7 Consequently, an updated prognostic grade group (GG) system from 1 to 5 has been proposed corresponding to Gleason scores of 6, 3 1 4, 4 1 3, 8, and 9 or 10, respectively, to address deficiencies with classic Gleason scoring. 4,8 The new system includes several pathologic grading updates that were incorporated in 2005 and introduces a simplified single score from 1 to 5 for improved clinical utility. The GG system has been collectively endorsed by the editors of the Corresponding author: Thomas J. Polascik, MD, Division of Urology, Department of Surgery, Duke University Medical Center, Box 2804, Yellow Zone, Durham, NC 27710; polas001@mc.duke.edu 1 Division of Urology, Duke University Medical Center, Durham, North Carolina; 2 Surgery Section, Durham Veterans Affairs Medical Center, Durham, North Carolina; 3 Department of Urology, Oregon Health and Science University Hospital, Portland, Oregon; 4 Department of Surgery, Veterans Affairs Healthcare System, Los Angeles, California; 5 Department of Urology, University of California, San Francisco, San Francisco, California; 6 Department of Urology, University of California, San Diego, San Diego, California; 7 Department of Urology, Veterans Affairs Medical Center, Augusta, Georgia; 8 Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California. Additional supporting information may be found in the online version of this article. DOI: /cncr.30844, Received: February 8, 2017; Revised: May 18, 2017; Accepted: May 24, 2017, Published online June 29, 2017 in Wiley Online Library (wileyonlinelibrary.com) 4122 Cancer November 1, 2017
2 Prostate Cancer Grade Group Validation/Schulman et al Figure 1. Consolidated Standards of Reporting Trials (CONSORT) diagram of the current study. leading urology journals and is now incorporated into the latest World Health Organization classification of prostate cancer. 9,10 The seminal article by Epstein et al in 2016 validated the GG system in 20,845 men after radical prostatectomy (RP) and 5501 men after radiotherapy using posttreatment prostate-specific antigen (PSA) recurrence as an endpoint. 4 Recently, validation of the GG system in other cohorts of men has demonstrated encouraging results, and several recent publications have reported the efficacy of prostate GGs for predicting long-term endpoints, including prostate cancer-specific mortality (PCSM) In this study, we tested the validity of the GG system for predicting multiple long-term oncologic endpoints in the Shared Equal Access Research (SEARCH) database, which consists of patients from 6 Veterans Affairs hospitals in the United States. The population is particularly interesting because of the high rate of sustained continuity of care, the presence of fewer socioeconomic confounders than other health care networks, and the large number of African American (AA) men (>32% in each GG group). MATERIALS AND METHODS Study Population After obtaining institutional review board approval, data from men who underwent primary RP at 1 of 6 participating Veterans Affairs hospitals in California, Georgia, and North Carolina were aggregated from the SEARCH database. 17 Available cases diagnosed between 2005 and 2015 were included. For long-term validation of the GGs, a range of preoperative parameters and the time to occurrence of multiple, clinically relevant, long-term endpoints were included. Clinical covariates included age, race, preoperative PSA, prostate volume, clinical stage, year of surgery, and surgical center. Long-term outcomes included biochemical recurrence (BCR), time to the initiation of secondary therapy, development of castrate-resistant prostate cancer (CRPC), development of metastatic disease, PCSM, and all-cause mortality (ACM). BCR was defined as 2 PSA values of 0.2 ng/ml or 1 PSA value >0.2 ng/ml after RP or the receipt of secondary therapy for an elevated PSA value. CRPC was defined as a PSA increase of 2 ng/ ml or as an increase 25% greater than the nadir after hormone treatment despite continuous therapy with a luteinizing hormone releasing agonist or antagonist or after orchiectomy. Metastatic disease was determined from bone scans or other imaging studies. PCSM was defined as the presence of metastatic, progressive CRPC at the time of death with no obvious indication of another cause of death, and ACM was determined from medical records. From a total of 2628 cases during the study period, 2509 were identified who had available biopsy Gleason scores, covariate clinical data, and long-term follow-up data (see Fig. 1). Biopsy Gleason scores were then used to Cancer November 1,
3 Original Article TABLE 1. Characteristics of the 2509 Patients Stratified by Grade Group No. of Patients (%) Characteristic GG 1 GG 2 GG 3 GG 4 GG 5 P All patients 909 (36.2) 813 (32.4) 398 (15.9) 279 (11.1) 110 (4.4) Age, y Median Q1, Q3 58, 65 58, 66 59, 66 59, 67 60, 68 Race.069 b White 541 (60) 433 (53) 228 (57) 150 (54) 72 (65) Black 345 (38) 352 (43) 152 (38) 118 (42) 35 (32) Other 23 (3) 28 (3) 18 (5) 11 (4) 3 (3) Year of surgery Median Q1, Q3 2006, , , , , 2013 Clinical tumor classification <.001 b T1 657 (72) 522 (64) 240 (60) 182 (65) 58 (53) T2-T4 252 (28) 291 (36) 158 (40) 97 (35) 52 (47) PSA, ng/ml Median Q1, Q3 4.4, , , , , 11.3 Surgery center <.001 b West LA 116 (13) 138 (17) 71 (18) 74 (27) 35 (32) Palo Alto 153 (17) 69 (8) 34 (9) 17 (6) 10 (9) Augusta 202 (22) 212 (26) 93 (23) 73 (26) 16 (15) Durham 190 (21) 194 (24) 58 (15) 29 (10) 8 (7) San Diego 106 (12) 124 (15) 73 (18) 61 (22) 32 (29) Asheville 142 (16) 76 (9) 69 (17) 25 (9) 9 (8) Percentage positive biopsy cores Median Q1, Q3 0.1, , , , , 0.8 Total no. of biopsy cores Median Q1, Q3 10, 12 11, 12 11, 12 12, 12 12, 12 No. of positive biopsy cores Median Q1, Q3 1, 4 3, 6 3, 7 2, 6 4, 9 TRUS prostate volume, cc Median a Q1, Q3 25.1, , , , , 44.5 Abbreviations: GG, grade group; PSA, prostate-specific antigen; Q1, 25th percentile; Q3, 75th percentile; TRUS, transrectal ultrasound. a P values were determined with the Kruskal-Wallis test. b P values were determined with the chi-square test. stratify the cohort into the 5 corresponding GGs, including GG 1 (909 men; 36.2%), GG 2 (813 men; 32.4%), GG 3 (398 men; 15.9%), GG 4 (279 men; 11.1%), and GG 5 (110 men; 4.4%). Statistical Analysis Characteristics among the 5 GGs were compared using rank-sum tests for continuous variables and chi-square tests for categorical variables. Continuous variables were summarized using median and 25th and 75th percentiles, and categorical variables were summarized using counts and percentages. Continuous covariates included age, prostate volume, preoperative PSA level (log-transformed), and year of surgery. Categorical covariates included race, clinical tumor classification (T1, T2-T4), and surgical center. Kaplan-Meier estimates were then graphed by GG for each endpoint, including BCR, secondary therapy, CRPC, metastatic disease, PCSM, and ACM. Differences in progression to the various endpoints were tested using the log-rank test. Cox proportionalhazards models were used to test the associations between GG and each outcome. Models were adjusted for clinical covariates. To account for changing of Gleason grading over time and the lack of centralized pathology review and the year of surgery and surgical center were also included as covariates. It is noteworthy that there were insufficient events to model PCSM and CRPC, and only univariable analyses were performed for metastatic disease and ACM because of low numbers of events. We also performed a sensitivity analysis for BCR, secondary therapy, and ACM adjusting for transrectal ultrasound-measured prostate volume, percentage of positive biopsy cores, number of positive cores, and percentage of positive cores among patients who had these 4124 Cancer November 1, 2017
4 Prostate Cancer Grade Group Validation/Schulman et al TABLE 2. Event Counts and Follow-Up for the 2509 Patients Stratified by Grade Group No. of Patients (%) Outcome Measure GG 1 GG 2 GG 3 GG 4 GG 5 P All patients 909 (36.2) 813 (32.4) 398 (15.9) 279 (11.1) 110 (4.4) Follow-up, mo <.001 1a Median Q1, Q3 46.0, , , , , 70.2 BCR 150 (17) 212 (26) 131 (33) 94 (34) 58 (53) <.001 b ADT 53 (6) 75 (9) 65 (16) 46 (16) 40 (36) <.001 b XRT 120 (13) 173 (21) 110 (28) 79 (28) 50 (45) <.001 b CRPC 0 (0) 2 (0) 7 (2) 7 (3) 8 (7) <.001 c Metastases 2 (0) 13 (2) 15 (4) 10 (4) 11 (10) < c Died of PC 0 (0) 1 (0) 5 (1) 4 (1) 4 (4) <.001 c ACM 65 (7) 55 (7) 33 (8) 21 (8) 10 (9) <.829 2b Abbreviations: ACM, all-cause mortality; ADT, androgen-deprivation therapy; BCR, biochemical recurrence; CRPC, castration-resistant prostate cancer; GG, grade group; PC, prostate cancer; Q1, 25th percentile; Q3, 75th percentile; XRT, radiation therapy. a P values were determined with the Kruskal-Wallis test. b P values were determined with the chi-square test. c P values were determined with the Fisher exact test. covariates available to determine whether the addition of these covariates impacted the results. In a secondary analysis, we tested whether the prognostic ability of GG varied by race (AA compared with Caucasian) in predicting each of the endpoints by including both main factors along with an interaction term in the same multivariable model. RESULTS Patient Characteristics Clinical characteristics of the study cohort stratified by GG are listed in Table 1. Higher GG was associated with older age, more recent year of surgery, higher clinical stage, higher PSA, and surgical center (all P <.001). Higher GG was also associated with a higher number of positive cores and a higher percentage of positive cores (P <.001). AA men comprised 41% (n ) of the overall cohort, ranging from 32% to 43% of each GG. Distribution according to race among the GGs was not statistically different (P 5.069). Primary Outcome Measures: Secondary Therapy, Clinical Progression, and Survival Primary outcome measures stratified by prostate GG are listed in Table 2. The median overall follow-up was 60 months (interquartile range, months), and the median PSA follow-up was 46 months (interquartile range, months). In total, 645 men (25.7%) had a BCR. Higher GG was associated with higher risk of BCR on univariable and multivariable analyses (P <.001). Two hundred seventy-nine (11.1%) patients received androgendeprivation therapy, and 532 (21.2%) received radiotherapy. Higher GG was associated with a greater risk of receiving secondary therapy on univariable and multivariable analyses (P <.001). During follow-up, 24 men (1%) developed CRPC, 51 (2%) developed metastases, 14 (0.56%) died from prostate cancer, and 184 (7.3%) died from any cause. On univariable analysis, higher GG was strongly associated with an increased risk of metastases (P <.001). Hazard ratios for select endpoints are listed in Tables 3 and 4. Kaplan-Meier estimates graphed by GG for each endpoint are depicted in Figure 2. Secondary Outcome: Impact of AA Race on the Predictive Utility of Prostate GG In total, there were 1596 AA men (38.1%) in the analysis cohort. Interactions between race and GG were tested for TABLE 3. Association of Grade Group With Biochemical Recurrence and Secondary Treatment BCR Secondary Treatment GG HR (95% CI) P HR (95% CI) P Unadjusted <.001 < Ref Ref ( ) 1.90 ( ) ( ) 2.76 ( ) ( ) 2.89 ( ) ( ) 6.36 ( ) Adjusted a <.001 < Ref Ref ( ) 1.78 ( ) ( ) 2.54 ( ) ( ) 2.87 ( ) ( ) 6.23 ( ) Abbreviations: BCR, biochemical recurrence; CI, confidence interval; GG, grade group; HR, hazard ratio. a Analyses were adjusted for age, race, prostate-specific antigen level, clinical stage, year of surgery, and surgical center. Cancer November 1,
5 Original Article TABLE 4. Association of Grade Group With Metastases and All-Cause Mortality a Metastases ACM GG HR (95% CI) P HR (95% CI) P Unadjusted < Ref Ref ( ) 1.38 ( ) ( ) 1.70 ( ) ( ) 1.59 ( ) ( ) 2.20 ( ) Abbreviations: ACM, all-cause mortality; CI, confidence interval; GG, grade group; HR, hazard ratio; Ref, reference category. a Fifty-one patients developed metastases, and there were184 deaths. select outcomes (Table 5). After adjusting for age, PSA, clinical stage, year of surgery, and surgical center, no significant interactions were observed between GG and race that predicted any measured outcomes, suggesting that GG has similar prognostic abilities in AA and Caucasian men. DISCUSSION Analyzing outcomes from an equal-access health system, we validated the GG stratification system for predicting multiple long-term oncologic outcomes after RP. Our findings support the use of GG for patient counseling and treatment planning and suggest the independent integration of each group into management algorithms. This represents 1 of the first published studies defining the predictive utility of the 5 updated GG tiers for multiple long-term endpoints. The current results are consistent with emerging findings from several other large studies. Spratt et al examined the impact of GG on biochemical recurrence-free survival in 3694 men after RP from 1994 to Those authors demonstrated statistically significant differences in 5-year actuarial biochemical recurrence-free survival stratified by GG for both preoperative biopsy grade and RP grade, with better utility than the 3-tier risk system. 16 Loeb and colleagues examined the National Prostate Cancer Registry of Sweden and identified 4325 men who underwent RP and 1555 men who received radiation therapy from 2005 to For both RP and radiation therapy, biopsy GG was a significant, independent predictor of 4-year biochemical recurrence-free survival. Mathieu et al examined data from more than 27,000 men at 7 European centers and validated GG at both biopsy and RP for predicting 4-year biochemical recurrence-free survival. 18 Recent reports have begun to examine long-term oncologic endpoints. Ham and coworkers examined mortality outcomes in men who had GG 4 and GG 5 disease diagnosed on either biopsy or RP specimens. The cohort spanned procedures performed between 1984 and 2014 and included 721 men who had original biopsy Gleason scores of 8 to 10 and 1047 men who had original RP Gleason scores of 8 to Those investigators observed worse PCSM and ACM in men with GG 5 (Gleason score 9) compared with GG 4 (Gleason score 8) for both biopsy and RP grading. Leapman et al examined oncologic outcomes in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry and noted that GG was associated with PCSM and metastatic bone progression across multiple primary treatment strategies, including conservative management and primary androgen deprivation. 14 In the largest population study to date, He et al reviewed the Surveillance, Epidemiology, and End Results database and observed that GG tiers predicted PCSM independent of primary treatment and clinical stage. 13 Our current study is unique and relevant for several important reasons. First, we have defined multiple, longterm, nonsurrogate endpoints for each biopsy GG that can be used as references for the management of all grades of prostate cancer. Complementing the findings by Ham et al for the highest Gleason groups, our findings for lower GG tiers are particularly useful for counseling the increasing number of men diagnosed with lower grade tumors who are considering active surveillance or partial gland ablation. Second, the analysis highlights the divergent biologic behavior within D Amico intermediate-risk disease when comparing GG 2 (G sum 3 1 4) and GG 3 (G sum 4 1 3) relative to GG 1 for important oncologic endpoints, including BCR, secondary therapy, and metastatic disease (Tables 3 and 4). This has important clinical implications, because some centers have expanded inclusion criteria for active surveillance. Third, the series is comprised of 41% AA men, including at least 32% in each GG tier, providing 1 of the largest published multiracial series to date. Poor inclusion of AA men in prostate cancer studies remains a significant research concern, and lack of available race-specific outcomes hinders both pretreatment and post-treatment counseling. 19 We identified no significant interactions between race and GG in predicting any outcomes, supporting the independent predictive utility of GG in AA men. Finally, our analysis was carried out at equal-access Veterans Affairs hospitals, 4126 Cancer November 1, 2017
6 Prostate Cancer Grade Group Validation/Schulman et al Figure 2. Kaplan-Meier estimates of each endpoint stratified by Grade Group. BCR indicates biochemical recurrence; CRPC, castration-resistant prostate cancer; PCSM, prostate cancer-specific mortality. removing potentially confounding socioeconomic barriers to treatment and continuity that may exist in other health care networks. There are several limitations to the current study that should be acknowledged. We performed a multicenter, retrospective study based on standard-read rather than specialized-read pathology reports, with no centralized pathology review, thus introducing confounding variability into the design. This may have contributed to the lack of prognostic difference observed between GG 3 and GG 4. We restricted the analysis to men who were diagnosed in 2005 and later to capture the impact of changes in pathologic grading introduced at that time. Although this limited the length of follow-up and frequency of adverse oncologic events likely to be observed with longer observation, the timeframe best reflects the predictive utility of the updated GG system. GG stratification and oncologic outcomes for patients in the Cancer November 1,
7 Original Article TABLE 5. Interactions Between Race and Grade Group Outcome SEARCH database from 1988 to 2015 are included in the Supporting Materials and in Supporting Figures 1 and 2 and Supporting Tables 1 through 4 (see online supporting information). We also restricted our analysis to the predictive utility of biopsy rather than RP Gleason scores and similarly used transrectal ultrasound rather than pathologic prostate volume, because these are the variables available to physicians for patient counseling and management decisions at the time of initial diagnosis. Although the RP Gleason score provides more accurate disease grading, the GG is used most commonly in the pretreatment phase, with an increasing number of men undergoing active surveillance or nonextirpative treatments. A final limitation was that we did not examine the influence of secondary therapies, including androgen deprivation and radiation therapy, on survival outcomes. Nonetheless, we observed that men with higher GG had greater receipt of secondary therapy and a trend toward worse PCSM. If not for the higher rate of secondary therapies, the worse survival with higher GG may have been even more pronounced. Conclusion This study validates the contemporary prostate biopsy GG system for predicting multiple long-term oncologic outcomes after RP. The data confirm the independent clinical utility of the GG in a large cohort of AA men, demonstrating that race does not impact prognostic utility. Continued integration of the GG system into clinical practice is warranted. FUNDING SUPPORT This study was supported by the National Institute of Health (grant K24CA to Stephen J. Freedland and P50CA92131 to William J. Aronson). CONFLICT OF INTEREST DISCLOSURES The authors made no disclosures. P Interaction a BCR.38 Adjuvant treatment.36 ACM.92 Abbreviations: ACM, all-cause mortality; BCR, biochemical recurrence. a Values were adjusted for age, PSA, clinical stage, year of surgery, and surgical center. AUTHOR CONTRIBUTIONS Ariel A. Schulman: Conceptualization, investigation, writing original draft, writing review and editing, and visualization. Lauren E. Howard: Methodology, software, validation, formal analysis, and writing review and editing. Kae Jack Tay: Conceptualization, methodology, and writing review and editing. Efrat Tsivian: Conceptualization, methodology, and writing review and editing. Christina Sze: Resources, visualization, and writing review and editing. Christopher L. Amling: Resources and writing review and editing. William J. Aronson: Resources and writing review and editing. Matthew R. Cooperberg: Resources and writing review and editing. Christopher J. Kane: Resources and writing review and editing. Martha K. Terris: Resources and writing review and editing. Stephen J. Freedland: Conceptualization, methodology, investigation, resources, writing review and editing, visualization, supervision, project administration, and funding acquisition. Thomas Polascik: Conceptualization, methodology, resources, writing review and editing, visualization, supervision, project administration and funding acquisition. REFERENCES 1. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111: Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40: Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol. 2005;23: Epstein JI, Zelefsky MJ, Sjoberg DD, et al. a contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol. 2016;69: Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate cancer, version J Natl Compr Canc Netw. 2016;14: Chan TY, Partin AW, Walsh PC, Epstein JI. Prognostic significance of Gleason score 314 versus Gleason score 413 tumor at radical prostatectomy. Urology. 2000;56: Jackson W, Hamstra DA, Johnson S, et al. Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy. Cancer. 2013;119: Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int. 2013;111: Zietman A, Smith J, Klein E, Droller M, Dasgupta P, Catto J. Consensus guidelines for reporting prostate cancer Gleason grade [serial online]. BJU Int. 2016;117: Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016;70: Berney DM, Beltran L, Fisher G, et al. Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome. Br J Cancer. 2016;114: Ham WS, Chalfin HJ, Feng Z, et al. New prostate cancer grading system predicts long-term survival following surgery for Gleason score 8-10 prostate cancer. Eur Urol. 2017;71: He J, Albertsen PC, Moore D, Rotter D, Demissie K, Lu-Yao G. Validation of a contemporary 5-tiered Gleason grade grouping using population-based data. Eur Urol. 2017;71: Leapman MS, Cowan JE, Simko J, et al. Application of a prognostic Gleason grade grouping system to assess distant prostate cancer outcomes. Eur Urol. 2017;71: Cancer November 1, 2017
8 Prostate Cancer Grade Group Validation/Schulman et al 15. Loeb S, Folkvaljon Y, Robinson D, Lissbrant IF, Egevad L, Stattin P. Evaluation of the 2015 Gleason grade groups in a nationwide population-based cohort. Eur Urol. 2016;69: Spratt DE, Cole AI, Palapattu GS, et al. Independent surgical validation of the new prostate cancer grade-grouping system. BJU Int. 2016;118: Wadhwa H, Terris MK, Aronson WJ, et al. Long-term oncological outcomes of apical positive surgical margins at radical prostatectomy in the Shared Equal Access Regional Cancer Hospital cohort. Prostate Cancer Prostatic Dis. 2016;19: Mathieu R, Moschini M, Beyer B, et al. Prognostic value of the new grade groups in prostate cancer: a multi-institutional European validation study. Prostate Cancer Prostatic Dis. 2017;20: Ahaghotu C, Tyler R, Sartor O. African American participation in oncology clinical trials focus on prostate cancer: implications, barriers, and potential solutions. Clin Genitourin Cancer. 2016;14: Cancer November 1,
Introduction. Original Article
bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: Results from the Shared Equal
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationDo all men with pathological Gleason score 8 10 prostate cancer have poor outcomes? Results from the SEARCH database
Do all men with pathological Gleason score 8 10 prostate cancer have poor outcomes? Results from the SEARCH database Sean Fischer*, Daniel Lin, Ross M. Simon*, Lauren E. Howard, William J. Aronson **,
More informationestimating risk of BCR and risk of aggressive recurrence after RP was assessed using the concordance index, c.
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTION OF AGGRESSIVE RECURRENCE AFTER RP SCHROECK et al. BJUI BJU INTERNATIONAL Do nomograms predict aggressive recurrence after radical
More informationPercent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer
Review Article Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer Meenal Sharma 1, Hiroshi Miyamoto 1,2,3 1 Department of Pathology and Laboratory
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationResults From the SEARCH Database
Cigarette Smoking Is Associated With an Increased Risk of Biochemical Disease Recurrence, Metastasis, Castration- Resistant Prostate Cancer, and Mortality After Radical Prostatectomy Results From the SEARCH
More informationMultiinstitutional Validation of the UCSF Cancer of the Prostate Risk Assessment for Prediction of Recurrence After Radical Prostatectomy
2384 Multiinstitutional Validation of the UCSF Cancer of the Prostate Risk Assessment for Prediction of Recurrence After Radical Prostatectomy Matthew R. Cooperberg, MD, MPH 1 Stephen J. Freedland, MD
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationPrognostic value of the Gleason score in prostate cancer
BJU International (22), 89, 538 542 Prognostic value of the Gleason score in prostate cancer L. EGEVAD, T. GRANFORS*, L. KARLBERG*, A. BERGH and P. STATTIN Department of Pathology and Cytology, Karolinska
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationCorrespondence should be addressed to Taha Numan Yıkılmaz;
Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationPredictive factors of late biochemical recurrence after radical prostatectomy
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2017, 47(3) 233 238 doi: 10.1093/jjco/hyw181 Advance Access Publication Date: 9 December 2016 Original Article Original
More informationTreatment Failure After Primary and Salvage Therapy for Prostate Cancer
307 Treatment Failure After Primary and Salvage Therapy for Prostate Cancer Likelihood, Patterns of Care, and Outcomes Piyush K. Agarwal, MD 1 Natalia Sadetsky, MD, MPH 2 Badrinath R. Konety, MD, MBA 2
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationSalvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes
ORIGINAL RESEARCH Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes Michael J. Metcalfe, MD ; Patricia Troncoso, MD 2 ; Charles C. Guo,
More informationUse of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence
Cancer Biomarkers 17 (2016) 83 88 83 DOI 10.3233/CBM-160620 IOS Press Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence Michael
More informationNIH Public Access Author Manuscript Clin Genitourin Cancer. Author manuscript; available in PMC 2015 October 01.
NIH Public Access Author Manuscript Published in final edited form as: Clin Genitourin Cancer. 2014 October ; 12(5): e181 e187. doi:10.1016/j.clgc.2014.02.008. The Impact of Differing Gleason Scores at
More informationPersonalized Therapy for Prostate Cancer due to Genetic Testings
Personalized Therapy for Prostate Cancer due to Genetic Testings Stephen J. Freedland, MD Professor of Urology Director, Center for Integrated Research on Cancer and Lifestyle Cedars-Sinai Medical Center
More informationOriginal Article. Cancer September 15,
Gleason Pattern 5 Is the Strongest Pathologic Predictor of Recurrence, Metastasis, and Prostate Cancer-Specific Death in Patients Receiving Salvage Radiation Therapy Following Radical Prostatectomy William
More informationLong-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence
EUROPEAN UROLOGY 59 (2011) 893 899 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Bertrand D. Guillonneau and Karim Fizazi on
More informationthree after the most recent release in These modifications were based primarily on data from clinical, not pathological, staging [1].
. 2010 BJU INTERNATIONAL Urological Oncology PATHOLOGICAL T2 SUB-DIVISIONS AS A PROGNOSTIC FACTOR IN PROSTATE CANCER CASO ET AL. BJUI BJU INTERNATIONAL Pathological T2 sub-divisions as a prognostic factor
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationSupplemental Information
Supplemental Information Prediction of Prostate Cancer Recurrence using Quantitative Phase Imaging Shamira Sridharan 1, Virgilia Macias 2, Krishnarao Tangella 3, André Kajdacsy-Balla 2 and Gabriel Popescu
More informationORIGINAL ARTICLE. Ja Hyeon Ku 1, Kyung Chul Moon 2, Sung Yong Cho 1, Cheol Kwak 1 and Hyeon Hoe Kim 1
(2011) 13, 248 253 ß 2011 AJA, SIMM & SJTU. All rights reserved 1008-682X/11 $32.00 www.nature.com/aja ORIGINAL ARTICLE Serum prostate-specific antigen value adjusted for non-cancerous prostate tissue
More informationUntreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes
Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes A. A. Hussein,* C. J. Welty,* N. Ameli,* J. E. Cowan, M. Leapman,*
More informationCONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM
RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title The quantitative Gleason score improves prostate cancer risk assessment Permalink https://escholarship.org/uc/item/9wq7g6k5 Journal Cancer,
More informationRisk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy
RESEARCH ARTICLE Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy Satoru Taguchi, Hiroshi Fukuhara*, Shigenori Kakutani,
More informationRadical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience
MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,
More informationDisease-specific death and metastasis do not occur in patients with Gleason score 6 at radical prostatectomy
Disease-specific death and metastasis do not occur in patients with at radical prostatectomy Charlotte F. Kweldam, Mark F. Wildhagen*, Chris H. Bangma* and Geert J.L.H. van Leenders Departments of Pathology,
More informationconcordance indices were calculated for the entire model and subsequently for each risk group.
; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 28 OCTOBER 1 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Predictors of Prostate Cancer Specific Mortality After Radical Prostatectomy or Radiation Therapy Ping Zhou,
More informationAccepted for publication 3 January 2005
Original Article RACIAL DIFFERENCES IN PSA DOUBLING TIME AND RECURRENCE TEWARI et al. In a multi-institutional study authors from the USA and Austria attempt to determine if there are differences in several
More informationin 32%, T2c in 16% and T3 in 2% of patients.
BJUI Gleason 7 prostate cancer treated with lowdose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure Richard G. Stock, Joshua Berkowitz, Seth R. Blacksburg and Nelson
More informationjournal of medicine The new england Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy abstract
The new england journal of medicine established in 1812 july 8, 4 vol. 31 no. 2 Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy Anthony V. D Amico, M.D.,
More informationShort ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy
Short ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy Sergey Shikanov, Pablo Marchetti, Vikas Desai, Aria Razmaria, Tatjana Antic, Hikmat Al-Ahmadie*, Gregory
More informationThe Role of the Pathologist Active Surveillance for Prostate Cancer
The Role of the Pathologist Active Surveillance for Prostate Cancer Thomas M. Wheeler, M.D. W. L. Moody, Jr., Professor and Chair Department of Pathology & Immunology Baylor College of Medicine Houston,
More informationPredictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era
ORIGINAL RESEARCH Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era Ahva Shahabi, MPH, PhD; 1* Raj Satkunasivam, MD; 2* Inderbir S. Gill, MD; 2 Gary Lieskovsky,
More informationGleason Scoring System 2017 JASREMAN DHILLON, MD ASSOCIATE PROFESSOR, DEPARTMENT OF ANATOMIC PATHOLOGY, MOFFITT CANCER CENTER, TAMPA, FLORIDA
Gleason Scoring System 2017 JASREMAN DHILLON, MD ASSOCIATE PROFESSOR, DEPARTMENT OF ANATOMIC PATHOLOGY, MOFFITT CANCER CENTER, TAMPA, FLORIDA Learners Objectives u Latest changes per ISUP 2014 that impact
More informationPROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS
PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS For patients with localized disease on biopsy* For patients with adverse pathology after prostatectomy Contact the GenomeDx Customer Support
More informationCorey C Foster 1, William C Jackson 1, Benjamin C Foster 1, Skyler B Johnson 1, Felix Y Feng 1 and Daniel A Hamstra 1,2*
Foster et al. Radiation Oncology 2014, 9:245 RESEARCH Open Access Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical
More informationLong-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with Radical Prostatectomy
Jpn J Clin Oncol 2012;42(6)541 547 doi:10.1093/jjco/hys043 Advance Access Publication 28 March 2012 Long-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with
More informationIn 2005, International Society of Urological Pathology
ORIGINAL ARTICLE Gleason Score 3+4=7 Prostate Cancer With Minimal Quantity of Gleason Pattern 4 on Needle Biopsy Is Associated With Low-risk Tumor in Radical Prostatectomy Specimen Cheng Cheng Huang, MD,*
More informationPSA is rising: What to do? After curative intended radiotherapy: More local options?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung
More informationJ Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 1 JANUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer
More informationDepartment of Urology, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.5.321 Original Article - Urological Oncology http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.5.321&domain=pdf&date_stamp=2014-05-16
More informationOncologic Outcomes of Patients With Gleason Score 7 and Tertiary Gleason Pattern 5 After Radical Prostatectomy
www.kjurology.org http://dx.doi.org/10.4111/kju.2013.54.9.587 Urological Oncology Oncologic Outcomes of Patients With Gleason Score 7 and Tertiary Gleason Pattern 5 After Radical Prostatectomy Yi-Hsueh
More informationRadical Prostatectomy:
Overtreatment and undertreatment Radical Prostatectomy: An Emerging Standard of Care for High Risk Prostate Cancer Matthew R. Cooperberg, MD,MPH UCSF Radiation Oncology Update San Francisco, CA April 2,
More informationIntroduction. Key Words: high-grade prostatic intraepithelial neoplasia, HGPIN, radical prostatectomy, prostate biopsy, insignificant prostate cancer
Prostate cancer after initial high-grade prostatic intraepithelial neoplasia and benign prostate biopsy Premal Patel, MD, 1 Jasmir G. Nayak, MD, 1,2 Zlatica Biljetina, MD, 4 Bryan Donnelly, MD 3, Kiril
More informationBJUI. Long-term overall survival and metastasis-free survival for men with prostate-specific antigenrecurrent
21 THE AUTHORS; 21 Urological Oncology DETERMINANTS OF SURVIVAL IN PSA-RECURRENT PROSTATE CANCER AFTER PROSTATECTOMY ANTONARAKIS ET AL. BJUI Long-term overall survival and metastasis-free survival for
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationJ Clin Oncol by American Society of Clinical Oncology INTRODUCTION
JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Active Surveillance in Younger Men With Prostate Cancer Michael S. Leapman, Janet E. Cowan, Hao G. Nguyen, Katsuto K. Shinohara, Nannette Perez,
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationDivision of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine, Durham, NC
LHRH AGONISTS: CONTEMPORARY ISSUES The Evolving Definition of Advanced Prostate Cancer Judd W. Moul, MD, FACS Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine,
More informationInformation Content of Five Nomograms for Outcomes in Prostate Cancer
Anatomic Pathology / NOMOGRAMS IN PROSTATE CANCER Information Content of Five Nomograms for Outcomes in Prostate Cancer Tarek A. Bismar, MD, 1 Peter Humphrey, MD, 2 and Robin T. Vollmer, MD 3 Key Words:
More informationA Comparative Analysis of Primary and Secondary Gleason Pattern Predictive Ability for Positive Surgical Margins after Radical Prostatectomy
168) Prague Medical Report / Vol. 112 (2011) No. 3, p. 168 176 A Comparative Analysis of Primary and Secondary Gleason Pattern Predictive Ability for Positive Surgical Margins after Radical Prostatectomy
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title Pathologic and biochemical outcomes among African American and Caucasian men with low-risk prostate cancer in the search database: Implications
More informationDivision of Oncology, S Orsola-Malpighi Hospital, Bologna, Italy. Department of Surgery, Cordoba University Medical School, Cordoba, Spain
Prostate cancer glands with cribriform architecture and with glomeruloid features should be considered as Gleason pattern 4 and not pattern 3 Daniele Minardi,1, Roberta Mazzucchelli,, Marina Scarpelli,
More informationChanges in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer
Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer S Egawa 1 *, H Okusa 1, K Matsumoto 1, K Suyama 1 & S Baba 1 1 Department
More informationPrognostic Value of Surgical Margin Status for Biochemical Recurrence Following Radical Prostatectomy
Original Article Japanese Journal of Clinical Oncology Advance Access published January 17, 2008 Jpn J Clin Oncol doi:10.1093/jjco/hym135 Prognostic Value of Surgical Margin Status for Biochemical Recurrence
More informationProviding Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More informationCorrelation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer
ORIGINAL ARTICLE Correlation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer Teng-Fu Hsieh, Chao-Hsian Chang, Wen-Chi Chen, Chien-Lung
More informationJure Murgic 1, Matthew H Stenmark 1, Schuyler Halverson 1, Kevin Blas 1, Felix Y Feng 1,2 and Daniel A Hamstra 1,3*
Murgic et al. Radiation Oncology 2012, 7:127 RESEARCH Open Access The role of the maximum involvement of biopsy core in predicting outcome for patients treated with dose-escalated radiation therapy for
More informationDepartment of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara , Japan 2
Advances in Urology Volume 2012, Article ID 204215, 7 pages doi:10.1155/2012/204215 Research Article Calculated Tumor Volume Is an Independent Predictor of Biochemical Recurrence in Patients Who Underwent
More informationImpact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis
Original Article Yonsei Med J 218 Jul;59(5):58-587 pissn: 513-5796 eissn: 1976-2437 Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity
More informationLong-term Survival of Extremely Advanced Prostate Cancer Patients Diagnosed with Prostate-specific Antigen over 500 ng/ml
Jpn J Clin Oncol 2014;44(12)1227 1232 doi:10.1093/jjco/hyu142 Advance Access Publication 19 September 2014 Long-term Survival of Extremely Advanced Prostate Cancer Patients Diagnosed with Prostate-specific
More informationSystems Pathology in Prostate Cancer. Description
Section: Medicine Effective Date: July 15, 2015 Subject: Systems Pathology in Prostate Cancer Page: 1 of 8 Last Review Status/Date: June 2015 Systems Pathology in Prostate Cancer Description Systems pathology,
More informationMedical Policy Manual. Topic: Systems Pathology in Prostate Cancer Date of Origin: December 30, 2010
Medical Policy Manual Topic: Systems Pathology in Prostate Cancer Date of Origin: December 30, 2010 Section: Laboratory Last Reviewed Date: April 2014 Policy No: 61 Effective Date: July 1, 2014 IMPORTANT
More informationChapter 6. Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma. Abstract
Chapter 6 Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma Vijaya Raj Bhatt 1, Carl M Post 2, Sumit Dahal 3, Fausto R Loberiza 4 and Jue Wang 4 * 1 Department
More informationGrading Prostate Cancer: Recent Changes and Refinements
USPSTF: 2012 Report on serum PSA Screening Recommendation rating of D Reduced screening, Reduced biopsies, reduced incidence Refinements currently occurring in 2017. WHY? Grading Prostate Cancer: Recent
More informationJournal of American Science 2018;14(1)
Salvage Radiotherapy Following Radical Prostatectomy: The Proper Timing and Clinical Benefits Mohamed F. Sheta 1, MD, Esam A. Abo-Zena 1, MD and Mohamed H. Radwan 2, MD 1 Department of Clinical Oncology,
More informationAram Kim 4, Myong Kim 1, Se Un Jeong 2, Cheryn Song 1, Yong Mee Cho 2, Jae Yoon Ro 3 and Hanjong Ahn 1*
Kim et al. BMC Urology (2018) 18:7 DOI 10.1186/s12894-018-0321-z RESEARCH ARTICLE Open Access Level of invasion into fibromuscular band is an independent factor for positive surgical margin and biochemical
More informationAndrogen deprivation therapy for treatment of localized prostate cancer and risk of
Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies Lauren P. Wallner, Renyi Wang, Steven J. Jacobsen, Reina Haque Department of Research and
More informationKey words: prostatic neoplasms, risk groups, biochemical recurrence, clinical progression, prostate cancer specific mortality
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2016, 46(8) 762 767 doi: 10.1093/jjco/hyw061 Advance Access Publication Date: 20 May 2016 Original Article Original Article
More informationExternal validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer
External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer Mathieu Roumiguié, Jean-Baptiste Beauval, Thomas Filleron*,
More informationBJUI. Effect of delaying surgery on radical prostatectomy outcomes: a contemporary analysis
BJUI BJU INTERNATIONAL Effect of delaying surgery on radical prostatectomy outcomes: a contemporary analysis Ruslan Korets, Catherine M. Seager, Max S. Pitman, Gregory W. Hruby, Mitchell C. Benson and
More informationAre Prostate Carcinoma Clinical Stages T1c and T2 Similar?
Clinical Urology Are Clinical Stages T1c and T2 Similar? International Braz J Urol Vol. 32 (2): 165-171, March - April, 2006 Are Prostate Carcinoma Clinical Stages T1c and T2 Similar? Athanase Billis,
More informationORIGINAL ARTICLE OPEN. AC Vidal 1, LE Howard 2, SX Sun 2, MR Cooperberg 3, CJ Kane 4, WJ Aronson 5,6, MK Terris 7,8, CL Amling 9 and SJ Freedland 1,2
Prostate Cancer and Prostatic Diseases (2017) 20, 72 78 www.nature.com/pcan OPEN ORIGINAL ARTICLE after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database
More informationHigh Risk Localized Prostate Cancer Treatment Should Start with RT
High Risk Localized Prostate Cancer Treatment Should Start with RT Jason A. Efstathiou, M.D., D.Phil. Assistant Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School 10
More informationClinical and biochemical outcomes of men undergoing radical prostatectomy or radiation therapy for localized prostate cancer
Original Article Radiat Oncol J 205;33():2-28 http://dx.doi.org/0.3857/roj.205.33..2 pissn 2234-900 eissn 2234-356 Clinical and biochemical outcomes of men undergoing radical prostatectomy or radiation
More informationAdam Raben M.D. Helen F Graham Cancer Center
Adam Raben M.D. Helen F Graham Cancer Center Is the biopsy sample representative of the extent of the disease in your patient with clinically low-risk prostate cancer? BIOPSY RP registry (n=8095) 3+3=6
More informationProposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy
Proposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy Richard J. Lee, Katherine S. Tzou, Michael G. Heckman*, Corey J.
More informationPROSTATE BIOPSY: IS AGE IMPORTANT FOR DETERMINING THE PATHOLOGICAL FEATURES IN PROSTATE CANCER?
Clinical Urology International Braz J Urol Official Journal of the Brazilian Society of Urology AGE AND PATHOLOGY OF PROSTATE CA Vol. 31 (4): 331-337, July - August, 2005 PROSTATE BIOPSY: IS AGE IMPORTANT
More informationGleason score = 8 prostate cancer: much more like Gleason score 9?
5 + 3 = 8 prostate cancer: much more like 9? Brandon A. Mahal, Vinayak Muralidhar*, Yu-Wei Chen, Toni K. Choueiri, Karen E. Hoffman, Jim C. Hu, Christopher J. Sweeney, James B. Yu**, Felix Y. Feng, Quoc-Dien
More informationInterval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer
DOI 10.1007/s00345-013-1125-0 ORIGINAL ARTICLE Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer D. M. Bolton A. Ta M. Bagnato
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationClinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center
Advances in Urology Volume 22, Article ID 64263, 8 pages doi:.55/22/64263 Clinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center D. Milonas, G. Smailyte,
More informationResearch Article Long-Term Oncological Outcomes for Young Men Undergoing Radical Prostatectomy for Localized Prostate Cancer
Hindawi BioMed Research International Volume 2017, Article ID 9858923, 6 pages https://doi.org/10.1155/2017/9858923 Research Article Long-Term Oncological Outcomes for Young Men Undergoing Radical Prostatectomy
More informationdoi: /j.ijrobp CLINICAL INVESTIGATION
CME doi:10.1016/j.ijrobp.2010.07.2004 Int. J. Radiation Oncology Biol. Phys., Vol. 81, No. 5, pp. 1293 1301, 2011 Copyright Ó 2011 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/$ - see
More informationPrior-Cancer Diagnosis in Men with Nonmetastatic Prostate Cancer and the Risk of Prostate-Cancer-Specific and All-Cause Mortality
Prior-Cancer Diagnosis in Men with Nonmetastatic Prostate Cancer and the Risk of Prostate-Cancer-Specific and All-Cause Mortality The Harvard community has made this article openly available. Please share
More informationSaira Khan. Chapel Hill Approved by: Andrew F. Olshan. Jeannette T. Bensen. Jianwen Cai. Matthew E. Nielsen. Melissa A.
DIABETES AND PROSTATE CANCER AGGRESSIVENESS AT DIAGNOSIS AND PROGRESSION IN WHITE AMERICANS AND BLACK AMERICANS FROM THE NORTH CAROLINA-LOUISIANA PROSTATE CANCER PROJECT (PCaP) Saira Khan A dissertation
More informationRadical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease
Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after
More information